Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
| Business Activity | PASS |
| Debt Ratio (0.15%) | PASS |
| Cash Ratio (0.64%) | FAIL |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-06 | -0.08 | Pending | -- |
| 2026-05-07 | -0.12 | -0.06 | +50.0% |
| 2026-02-27 | 0.16 | -0.10 | -163.2% |
| 2025-11-05 | -0.16 | -0.13 | +17.5% |
| 2025-08-07 | -0.19 | -0.16 | +14.7% |
| 2025-05-14 | -0.28 | -0.17 | +39.3% |
| 2025-02-28 | -0.22 | -0.27 | -24.2% |
| 2024-11-07 | -0.26 | -0.25 | +3.6% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | -$3.5M | -$2.9M | — | -$3.5M | -0.06 |
| 2025-12-31 | — | -$6.5M | -$5.9M | — | -$6.7M | — |
| 2025-09-30 | — | -$7.7M | -$7.1M | — | -$8.0M | -0.13 |
| 2025-06-30 | — | -$9.8M | -$9.2M | — | -$10.2M | -0.16 |
| 2025-03-31 | — | -$9.9M | -$9.4M | — | -$10.4M | -0.17 |
| 2024-09-30 | — | — | — | — | — | -0.25 |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-03-19 | DOUGLAS RICHARD H | Director | 70,000 | $128.1K |
| 2026-03-18 | ALFIERI MICHAEL L | Chief Financial Officer | 5,000 | $7.1K |
| 2025-08-13 | ALFIERI MICHAEL L | Chief Financial Officer | 2,500 | $13.2K |
| 2025-08-11 | MACHATHA STEPHEN | Officer | 22,073 | $113.7K |
| 2025-04-03 | PERCEPTIVE ADVISORS L L C | Beneficial Owner of more than 10% of a Class of Security | 3,400,000 | $4.8M |
| 2024-08-12 | MACHATHA STEPHEN | Officer | 16,041 | $76.0K |
| 2024-08-12 | GREENBERG BRUCE | Chief Financial Officer | 10,834 | $51.3K |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Knoll Capital Management, LLC | 5.5M | $8.5M | 0.1% |
| Blackrock Inc. | 3.8M | $5.8M | 0.1% |
| AQR Capital Management, LLC | 2.8M | $4.4M | 0.0% |
| Vanguard Capital Management LLC | 2.4M | $3.7M | 0.0% |
| Kingdon Capital Management LLC | 2.2M | $3.3M | 0.0% |
| 683 Capital Management LLC | 1.5M | $2.3M | 0.0% |
| Shaw D.E. & Co., Inc. | 1.4M | $2.2M | 0.0% |
| Geode Capital Management, LLC | 1.3M | $1.9M | 0.0% |
| State Street Corporation | 1.1M | $1.7M | 0.0% |
| Millennium Management Llc | 995.2K | $1.5M | 0.0% |
$44.0M
2.22
1.149
5
$15.5M
1.60
4.36
0.1%
7
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-06 | $-0.08 | Pending | — |
| 2026-05-07 | $-0.12 | $-0.06 | +50.0% |
| 2026-02-27 | $0.16 | $-0.10 | -163.2% |
| 2025-11-05 | $-0.16 | $-0.13 | +17.5% |
| 2025-08-07 | $-0.19 | $-0.16 | +14.7% |
| 2025-05-14 | $-0.28 | $-0.17 | +39.3% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($7.60, 5 analysts) | |||
| 10 | $16.75 | +$59.20 (354%) | 22.8R |
| 50 | $83.75 | +$296.00 (354%) | 22.8R |
| 100 | $167.50 | +$592.00 (354%) | 22.8R |
- Elevated short interest (4.36 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| ASO | 0.370 |
| RH | 0.338 |
| VPG | 0.298 |
| VSH | 0.289 |
| W | 0.283 |
| Ticker | Correlation |
|---|---|
| EGRX | -0.182 |
| DHBK.QA | -0.180 |
| EOAN.DE | -0.178 |
| SVT.L | -0.174 |
| EXCL.JK | -0.168 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.